Century Therapeutics (NASDAQ:IPSC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Century Therapeutics in a research report on Tuesday, September 29th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $4.75.
View Our Latest Research Report on IPSC
Century Therapeutics Stock Up 2.0%
Shares of NASDAQ:IPSC opened at $1.49 on Friday. The company has a market cap of $269.61 million, a price-to-earnings ratio of -1.60 and a beta of 1.67. The firm's 50-day simple moving average is $1.74 and its 200-day simple moving average is $2.09. Century Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $3.04.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, research analysts forecast that Century Therapeutics will post -0.51 EPS for the current year.
Hedge Funds Weigh In On Century Therapeutics
Several large investors have recently added to or reduced their stakes in IPSC. Spark Investment Management LLC purchased a new stake in shares of Century Therapeutics during the second quarter valued at approximately $145,000. AXQ Capital LP acquired a new position in shares of Century Therapeutics during the second quarter worth $145,000. Wellington Management Group LLP purchased a new position in shares of Century Therapeutics in the second quarter valued at $201,000. Seven Fleet Capital Management LP purchased a new position in shares of Century Therapeutics in the second quarter valued at $10,652,174. Finally, Bank of America Corp DE purchased a new position in shares of Century Therapeutics in the second quarter valued at $389,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.
About Century Therapeutics
(
Get Free Report)
Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.
Century's pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Century Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Century Therapeutics wasn't on the list.
While Century Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.